I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 8 studies | 31% ± 14% | |
| endothelial cell of lymphatic vessel | 3 studies | 22% ± 7% | |
| GABAergic neuron | 3 studies | 29% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 8 studies | 31% ± 14% | |
| endothelial cell of lymphatic vessel | 3 studies | 22% ± 7% | |
| GABAergic neuron | 3 studies | 29% ± 13% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 32% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 98% | 827.01 | 567 / 578 | 72% | 8.06 | 826 / 1155 |
| adrenal gland | 76% | 175.61 | 196 / 258 | 72% | 22.03 | 165 / 230 |
| prostate | 80% | 265.40 | 195 / 245 | 65% | 4.00 | 328 / 502 |
| breast | 92% | 330.79 | 421 / 459 | 44% | 2.85 | 494 / 1118 |
| brain | 58% | 560.55 | 1527 / 2642 | 77% | 11.62 | 545 / 705 |
| skin | 64% | 193.68 | 1161 / 1809 | 46% | 6.75 | 219 / 472 |
| thymus | 90% | 303.57 | 586 / 653 | 20% | 1.40 | 123 / 605 |
| blood vessel | 96% | 676.22 | 1282 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 94% | 418.04 | 1128 / 1204 | 0% | 0 | 0 / 0 |
| kidney | 15% | 23.62 | 13 / 89 | 61% | 13.52 | 551 / 901 |
| intestine | 51% | 78.02 | 495 / 966 | 24% | 1.36 | 129 / 527 |
| stomach | 34% | 64.49 | 122 / 359 | 35% | 2.52 | 101 / 286 |
| eye | 0% | 0 | 0 / 0 | 64% | 5.67 | 51 / 80 |
| pancreas | 2% | 2.21 | 7 / 328 | 61% | 5.22 | 108 / 178 |
| lymph node | 0% | 0 | 0 / 0 | 62% | 6.77 | 18 / 29 |
| bladder | 33% | 115.10 | 7 / 21 | 25% | 1.41 | 127 / 504 |
| esophagus | 36% | 64.39 | 526 / 1445 | 19% | 1.24 | 35 / 183 |
| uterus | 34% | 62.84 | 58 / 170 | 17% | 2.02 | 77 / 459 |
| heart | 40% | 62.41 | 342 / 861 | 0% | 0 | 0 / 0 |
| liver | 6% | 6.88 | 13 / 226 | 26% | 2.04 | 105 / 406 |
| ovary | 16% | 46.04 | 28 / 180 | 15% | 0.80 | 64 / 430 |
| tonsil | 0% | 0 | 0 / 0 | 18% | 1.31 | 8 / 45 |
| muscle | 13% | 20.06 | 106 / 803 | 0% | 0 | 0 / 0 |
| spleen | 12% | 38.67 | 29 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 1% | 2.18 | 12 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0015015 | Biological process | heparan sulfate proteoglycan biosynthetic process, enzymatic modification |
| GO_0006024 | Biological process | glycosaminoglycan biosynthetic process |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0008467 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 1 activity |
| GO_0008146 | Molecular function | sulfotransferase activity |
| GO_0033871 | Molecular function | [heparan sulfate]-glucosamine 3-sulfotransferase 2 activity |
| Gene name | HS3ST2 |
| Protein name | Sulfotransferase (EC 2.8.2.-) Heparan sulfate glucosamine 3-O-sulfotransferase 2 (EC 2.8.2.29) (Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 2) (3-OST-2) (Heparan sulfate 3-O-sulfotransferase 2) (h3-OST-2) |
| Synonyms | 3OST2 UNQ2442/PRO5004 |
| Description | FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit on heparan sulfate . Catalyzes the O-sulfation of glucosamine in GlcA2S-GlcNS . Unlike HS3ST1/3-OST-1, does not convert non-anticoagulant heparan sulfate to anticoagulant heparan sulfate . . |
| Accessions | H3BMR2 ENST00000261374.4 ENST00000473392.1 Q9Y278 |
